San Francisco startup Structure Therapeutics is also focusing on an oral, the moment-daily GLP-1 drug named GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June whenever a mid-phase study showed normal weight loss of all-around 6% and it programs to start A different mid-phase demo toward the end of this calendar year—that founder